
Reata Pharmaceuticals (RETA) Stock Forecast & Price Target
Reata Pharmaceuticals (RETA) Analyst Ratings
Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 36%
Hold 43%
Sell 0%
Strong Sell 0%
Reata Pharmaceuticals (RETA) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 36% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Reata Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of Reata Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Reata Pharmaceuticals (RETA) Analyst Forecast & Price Prediction
Get the latest Reata Pharmaceuticals (RETA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in Reata Pharmaceuticals (RETA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Reata Pharmaceuticals (RETA) Forecast
Analysts have given Reata Pharmaceuticals (RETA) a Buy based on their latest research and market trends.
According to 14 analysts, Reata Pharmaceuticals (RETA) has a Buy consensus rating as of Jul 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $144.57, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $144.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.